Ocular Therapeutix™ to Present at the Jefferies Virtual Healthcare Conference
May 29 2020 - 8:00AM
Business Wire
Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical
company focused on the formulation, development, and
commercialization of innovative therapies for diseases and
conditions of the eye, today announced that Antony Mattessich,
President and Chief Executive Officer of Ocular Therapeutix, will
participate in a fireside chat at the Jefferies Virtual Healthcare
Conference on Thursday, June 4, 2020 at 2:30 PM EDT.
In addition to the presentation, the management team will host
investor meetings at the conference. Investors participating in the
conference who are interested in meeting with Ocular Therapeutix
management should contact their Jefferies representative.
A live webcast of the presentation can be accessed by visiting
the Investors section of the Company’s website at
investors.ocutx.com.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused
on the formulation, development, and commercialization of
innovative therapies for diseases and conditions of the eye using
its proprietary bioresorbable hydrogel-based formulation
technology. Ocular Therapeutix’s first commercial drug product,
DEXTENZA® (dexamethasone ophthalmic insert), is FDA-approved for
the treatment of ocular inflammation and pain following ophthalmic
surgery. Ocular Therapeutix recently completed a Phase 3 clinical
trial evaluating DEXTENZA for the treatment of ocular itching
associated with allergic conjunctivitis and intends to file an sNDA
for this additional indication by the end of 2020. OTX-TP
(intracanalicular travoprost insert) is an intracanalicular insert
in clinical development for the reduction of intraocular pressure
in patients with primary open-angle glaucoma and ocular
hypertension. The Company’s earlier stage development assets
currently in Phase 1 trials include OTX-TIC (travoprost
intracameral implant) for the reduction of intraocular pressure in
patients with primary open-angle glaucoma and ocular hypertension,
OTX-CSI (cyclosporine intracanalicular insert) for the treatment of
the signs and symptoms of dry eye disease and OTX-TKI (axitinib
intravitreal implant) for the treatment of retinal diseases. Also,
in collaboration with Regeneron, Ocular Therapeutix is currently
developing on OTX-IVT (aflibercept suprachoroidal injection), an
extended-delivery formulation of aflibercept for the treatment of
retinal diseases. Ocular Therapeutix's first product, ReSure®
Sealant, is FDA-approved to seal corneal incisions following
cataract surgery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200529005124/en/
Investors Ocular Therapeutix Donald Notman Chief
Financial Officer dnotman@ocutx.com
or
Westwicke, an ICR Company Chris Brinzey, 339-970-2843
chris.brinzey@westwicke.com
Media Ocular Therapeutix Scott Corning Senior Vice
President, Commercial scorning@ocutx.com
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Sep 2023 to Sep 2024